The largest database of trusted experimental protocols

Bleomycin

Manufactured by Santa Cruz Biotechnology
Sourced in United States

Bleomycin is a chemotherapeutic agent used in the treatment of various types of cancer. It is a mixture of glycopeptide antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin functions as a DNA-damaging agent, primarily inducing DNA strand breaks. Its core function is to disrupt cellular processes and induce cell death in rapidly dividing cancer cells.

Automatically generated - may contain errors

9 protocols using bleomycin

1

Generation and Validation of Brca1 Mutants

Check if the same lab product or an alternative is used in the 5 most similar protocols
MMC (SCBT), Cisplatin (Sigma Aldrich), ABT-888 (SelleckChem, Houston, TX) and Bleomycin (SCBT, Santa Cruz, CA) were purchased in DMSO or prepared as stocks in DMSO. The Brca1 deletion mutants36 (link) are HA-tagged and correspond to deletions within the Brca1 protein as illustrated in Figure 6d. The Brca1 ΔM3 mutant (aa 1290–1530) was generated from full length HA-Brca1 plasmid37 using methods described in Gibson Assembly Cloning Kit (New England BioLabs) and primer sequences: BRCA1-305-F: CAGAATGAATGTAGAAAAGGCTG, BRCA1-305-1290-del-Rev: gttgctcctccacatcaacaacACATTTTGTTTCCTCACTAAG, BRCA1-305-1290-del-For: cttagtgaggaaacaaaatgtGTTGTTGATGTGGAGGAGCAAC, pcDNA-Xho-rev: TAGGGCCCTCTAGATGCATGC. XhoI and EcoRI restriction digestion and sequencing validated the correct insertion and sequence. The full length myc-Wwox plasmid13 (link) and deletion mutants15 (link) were previously described.
+ Open protocol
+ Expand
2

Generation of PLK4-inducible Stable Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
To generate PLK4‐inducible stable cell lines from OVCAR8 and SKOV3 cells, we used a doxycycline‐inducible PLK4 lentiviral expression system (Holland et al, 2012 (link)). Viruses were produced in HEK293T cells, co‐transfected with two other vector plasmids using lipofectamine 2000: a vesicular stomatitis virus envelope expression plasmid (Vsvg) and a second‐generation packaging plasmid (pPax2). Viral particles were then used to infect OVCAR8 and SKOV3 cell lines for 24 h. Infected cells were selected using bleomycin 50 μg/ml (Santa cruz Biotechnology #sc200134A) for 15 days. Newly generated stable cell lines iOVCAR8 and iSKOV3 were then expanded in DMEM/F12 media supplemented with 10% tetracycline‐free fetal bovine serum (FBS, Dutscher #S181T), streptomycin (100 μg/ml,), and penicillin (100 U/ml). To induce PLK4 overexpression, cells were treated with doxycycline (1 μg/ml) for 96 h.
+ Open protocol
+ Expand
3

DNA Damage Response Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following specific antibodies were used in this study: Anti‐γH2AX (#2577), anti‐γ‐H2AX (#9718) and anti‐GAPDH (#51332), anti‐H4K8ac (#2594), anti‐ATM (#2873), anti‐ATM (#92356), anti‐pATM (#5883S), anti‐ATR (#13934), anti‐pATR (#2853), anti‐CHK1(#2360), anti‐pCHK1 (#2348), anti‐CHK2 (#6334), anti‐pCHK2 (#2197), anti‐FLAG (8146), anti‐MYC (71D10) and anti‐TIP60 (#12058) were all purchased from Cell Signaling Technology (Boston, MA). anti‐TIP60 (#10398) was purchased from Abnova. anti‐ATM (#ET‐1606‐20) was purchased from Human Technology. Anti‐FAM135B (SAB2104963) was purchased from Sigma‐Aldrich (Merck Darmstadt, Germany). Anti‐FLAG (ab205606) and anti‐53BP1 (ab36823) antibodies were acquired from Abcam (England); anti‐GST (HT601) was acquired from Santa Cruz (Dallas, USA); bleomycin (BLM, radiomimetic drug), etoposide (ETO) and cisplatin (CDDP, a chemotherapy drug that can cause DNA double‐chain rupture as a DNA damage inducer) purchased from Selleck (America). We describe all the antibodies and drugs in Tables S1 and S2.
+ Open protocol
+ Expand
4

EPRS and STAT Signaling Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
All cytokines and growth factors including TGFβ1 were purchased from Peprotech (Rocky Hill, NJ, United States). Hydroxyproline assay kits, and CCl4 were purchased from Sigma-Aldrich (St. Louis, MO, United States). Bleomycin and target specific pooled siRNAs siSTAT3 and siSTAT6 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States). EPRS in pEXPR-103-Strep vector (IBA Lifesciences, Göettingen, Germany) were gifts from Dr. Myung Hee Kim at the Korea Research Institute of Bioscience and Biotechnology (KRIBB, Daejeon, Korea). EPRS (1–1440 amino acids) consists of ERS (1–687 amino acids) and PRS (935–1,440 amino acids) linked via non-catalytic WHEP repeat domains (688–934 amino acids) (Ray and Fox, 2014 (link)). The PRS domain of EPRS was cloned into pEXPR-103-Strep vector (IBA Lifesciences). pRc/CMV-WT STAT3 was previously described (Choi et al., 2009 (link)) and pCMV-STAT6-IRES-Neo was a gift from Axel Nohturfft (Addgene plasmid # 35482). Adenovirus expressing SMAD2 or SMAD3 were described previously (Lee et al., 2005 (link)).
+ Open protocol
+ Expand
5

Cell Culture and Treatment Conditions

Check if the same lab product or an alternative is used in the 5 most similar protocols
A549, HeLa, 293T and U2OS cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS), and 50 U ml−1 penicillin and 50 ng ml−1 streptomycin (Gibco). None of the cell lines used in this study are listed in the database of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee70 (link). The A549 cell line was a gift from the Bradner Lab at Dana-Farber Cancer Institute and was verified by short tandem repeat (STR) profiling. The HeLa and U2OS cells originated from the Jasin Lab at Memorial Sloan Kettering Cancer Center. The 293T cells were gifts from the Alt Lab at Boston Children’s Hospital. Cells were tested for mycoplasma contamination by the IDEXX Laboratories or using the Lonza Mycoplasma kit. Puromycin (Gibco) selection in A549 and 293T cells was at 1.0 μg ml−1. Hygromycin B (Invitrogen) selection in A549 cells was at concentration (200 μg ml−1). Cell synchronization of A549 cells was achieved by growing cells to confluence, reducing FBS to 0.1% for 72 h and releasing cells into DMEM with 20% FBS. A549 cells were treated at the indicated concentrations of pyridostatin (Sigma Aldrich), PhenDC3 (Polysciences), ME0328 (Selleck), KU0058948 (Axon MedChem) or Bleomycin (Santa Cruz Biotechnology) when indicated. All cells were cultured under normal oxygen conditions (21% O2, 5% CO2, 37 °C).
+ Open protocol
+ Expand
6

Assessing DNA Damage Response in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
To assess the DDR, 293T, SLK or HDMVEC cells were incubated with 5 μM of bleomycin (Santa Cruz Biotechnology, sc-200134) for 30 min at 37°C, prior to harvesting for immunoblot. To assess the DDR in the γH2AX knockout, cells were treated with 5 μM of bleomycin for 5 min before assessing by western blot.
+ Open protocol
+ Expand
7

Quantifying Mitochondrial DNA Damage

Check if the same lab product or an alternative is used in the 5 most similar protocols
After exposure to room air or hyperoxia, or treatment with bleomycin (Santa Cruz, Dallas, TX), cells were trypsinized, pelleted and stored at −20 °C until analysis. Total DNA was isolated using the DNeasy Blood & Tissue kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Ten micrograms of DNA was digested with BamHI and subjected to gel electrophoresis on a 0.6% agarose gel without ethidium bromide. DNA was transferred to a nylon membrane (MSI MagnaGraph, 0.45 µM) using standard southern blotting technique [33] . A complimentary DNA fragment encoding the 12S and 16S rRNA region of mtDNA (5′-GGTCACACGATTAACCCAAG-3′ and 5′-GTTGGTTGATTGTAGATATTGG-3′) was radiolabeled using the Prime-a-Gene kit (Promega, Madison, WI) with α32P-dCTP and hybridized to the DNA on the blot overnight. Hybridization was visualized on blue x-ray film (Laboratory Products Sales, Rochester, NY).
+ Open protocol
+ Expand
8

Lung Fibrosis Induction in Murine EPRS Knockout Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Wildtype (WT) EPRS+/+ (n = 4 for vehicle and n = 9 for bleomycin) and EPRS−/+ hetero-knockout (n = 5 for vehicle and n = 7 for bleomycin) C57BL/6 mice were housed in a specific pathogen-free room with controlled temperature and humidity. Mouse protocol and animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University (SNU-161201-1-3). For the lung fibrosis model, bleomycin (Santa Cruz Biotechnology) was dissolved in sterilized saline and intratracheal instillation was performed through surgically exposed trachea as a single dose of 1 mg/kg in 100 μl solution per animal. Mice were sacrificed 4 weeks post-intratracheal instillation. Lung tissue samples were snap frozen in liquid nitrogen for western blot, qPCR, and hydroxyproline analysis, or fixed in 4% formaldehyde in PBS for histological analysis.
+ Open protocol
+ Expand
9

Bleomycin-induced Pulmonary Fibrosis Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Wild-type C57BL/6 mice (4 weeks old) were purchased from Orient Bio Inc. (Seongnam, South Korea). Global TM4SF5-knockout C57BL/6 mice (Tm4sf5−/−) were generated by Macrogen (Seoul, South Korea). Briefly, base pairs of genomic TM4SF5 surrounding exon 1 were deleted using the RGEN/Cas9 genetic scissor. The genotypes of both wild-type and Tm4sf5−/− mice were determined by PCR analysis of genomic DNA obtained from tail clippings from 3-week-old animals. Male wild-type and Tm4sf5−/− mice at 8 weeks old were treated with either saline vehicle for the control or bleomycin (1 mg/kg, Santa Cruz Biotechnology) by intratracheal injection on day 0. Mice were sacrificed on day 28 for histological analysis and hydroxyproline assay.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!